Hyperbaric oxygen therapy (HBOT) resolves or significantly improves late radiation tissue injury 39% more often than standard care, according to a 2023 Cochrane review of 18 randomized trials and 1,071 patients (RR 1.39, 95% CI 1.02-1.89).1 It is FDA-cleared and UHMS-approved for delayed radiation injury, works best for cystitis, proctitis, and osteoradionecrosis, and is covered by Medicare. It does not help radiation injury to neural tissue.
Higher likelihood of complete resolution or significant improvement of late radiation tissue injury with HBOT versus standard care (RR 1.39, 18 RCTs, 1,071 patients).
Cochrane review, Lin et al., 2023
Why Does Radiation Damage Keep Worsening Years After Treatment?
Radiation therapy damages the DNA of dividing cancer cells, but it also injures the small blood vessels supplying nearby healthy tissue. That vascular damage does not appear immediately. Over months and years, the vessels become progressively obliterated through endarteritis obliterans: walls thicken, blood flow falls, and tissue becomes chronically oxygen-deprived.
This creates a self-perpetuating cycle known as the “three-H” pathway: hypoxia (low oxygen), hypovascularity (few vessels), and hypocellularity (few cells). Oxygen-starved tissue cannot heal. Any trauma, surgery, or infection in a previously irradiated field heals poorly or not at all, fibrosis accumulates, and tissue may break down into wounds, fistulas, bone death, or organ dysfunction. HBOT targets this root cause rather than the symptoms.
Which Radiation Injuries Does HBOT Treat Best?
HBOT’s benefit varies sharply by tissue. It is strongest for bladder and jaw injury, moderate for bowel and soft tissue, and absent for neural tissue. The Cochrane review quantifies most of these outcomes directly.
HBOT Outcomes by Radiation Injury Type
| Injury type | HBOT effect | Evidence | Source |
|---|---|---|---|
| Radiation cystitis | 84-90% response | Strong | Meta-analyses |
| Osteoradionecrosis (jaw) | RR 1.3 mucosal coverage (NNTB 5) | Strong | Cochrane 2023 |
| Proctitis | RR 1.72 improvement (NNT 5) | Moderate | Cochrane 2023 |
| Soft tissue flap survival | RR 8.7 (95% CI 2.7-27.5) | Moderate | Cochrane 2023 |
| Brain / spinal cord | No demonstrated benefit | Limited | Cochrane 2023 |
Radiation Cystitis
One of the most common and debilitating radiation injuries, radiation cystitis affects the bladder after pelvic radiation for prostate, cervical, rectal, or bladder cancers, causing urinary frequency, urgency, pain, and bleeding. HBOT has some of its strongest evidence here, with response rates of 84 to 90% across meta-analyses. Our dedicated radiation cystitis and HBOT article covers the clinical detail.
Osteoradionecrosis (Jaw Bone Death)
Head and neck cancer survivors who receive radiation to the jaw are at risk for osteoradionecrosis (ORN), where the jawbone loses its blood supply and begins to die. Tooth extractions in irradiated jaw tissue carry particularly high risk. The Cochrane review found HBOT achieved mucosal coverage in ORN at RR 1.3 (95% CI 1.1-1.6, NNTB 5) and reduced wound breakdown risk (RR 4.2, 95% CI 1.1-16.8, NNTB 4).1
Radiation Proctitis
Radiation proctitis involves damage to the rectum and lower bowel after pelvic radiation, causing bleeding, diarrhea, urgency, and in severe cases fistulas or obstruction. The Cochrane review found a relative risk of 1.72 for improvement or cure with HBOT, with a number needed to treat of 5.1
Soft Tissue Radiation Necrosis
Radiation can cause necrosis in soft tissue anywhere in a treatment field: breast, chest wall, pelvic floor, and more. HBOT supports healing when surgical debridement and reconstruction are needed in irradiated areas by improving the vascularity of the tissue bed. The Cochrane review found surgical flap survival was markedly improved with HBOT (RR 8.7, 95% CI 2.7-27.5, NNTB 4).1
Improvement in surgical flap survival in irradiated tissue with HBOT, among the largest effect sizes in the evidence base.
Cochrane review, Lin et al., 2023
Radiation-Induced Brain and Spinal Cord Injury
Radiation necrosis of the brain or spinal cord is a serious complication of CNS radiation. HBOT has been used as an adjunct in some cases, but the Cochrane review found no demonstrated benefit for neural tissue injury.1 Expectations should be calibrated accordingly: this is the one radiation injury category where the evidence does not support HBOT.
How Does HBOT Work for Radiation Damage?
HBOT’s mechanism here is well understood. By raising plasma oxygen levels at 2.0 to 2.5 ATA, it reaches the chronically hypoxic tissue that radiation has starved of blood supply. With repeated sessions, HBOT stimulates angiogenesis, the growth of new blood vessels into ischemic tissue, so patients rebuild a durable vascular network rather than getting a temporary oxygen boost.
This is why response to HBOT for radiation injury tends to last. A large US registry study of 2,538 patients found symptom improvement or resolution rates of 76.7% to 92.6% depending on injury type, with osteoradionecrosis showing the highest scores.3
Radiation injury patients in the largest US registry study, with 77 to 93% improvement rates by injury type.
Niezgoda et al., 2016
What Does the Research Say?
Radiation tissue injury is one of the most evidence-backed HBOT applications. UHMS formally endorses it as an approved indication, the FDA has cleared HBOT for delayed radiation tissue injury, and Medicare and most commercial insurers cover it when documented. Beyond the Cochrane review, a 2025 systematic review of 17 studies and 640 head and neck cancer patients found positive outcomes in 14 of 17 studies (82%), with significant results in 11.4 A 2025 review focused on bowel and bladder injury confirmed a beneficial effect across 3 RCTs (273 patients), though heterogeneous designs prevented pooled meta-analysis.5
What Does the HBOT Protocol Look Like?
Standard radiation injury protocols involve 30 to 40 sessions at 2.0 to 2.4 ATA, each running about 90 minutes, typically five days per week for a six to eight week course. For osteoradionecrosis treated surgically, a combined protocol is common: roughly 20 sessions before surgery and 10 after. Improvement is gradual, and the angiogenic response continues for weeks to months after the final session. Our session guide explains the logistics, and radiation injury outcomes details response by tissue type.
Does Insurance Cover HBOT for Radiation Injury?
Radiation injury is one of the best-covered HBOT indications. Medicare covers HBOT for delayed radiation tissue damage when criteria are met, including documented radiation history, an adequate trial of conventional treatment, and treatment at an approved facility. Most commercial insurers follow Medicare’s guidelines, and prior authorization is almost always required. Our insurance coverage guide walks through the process. For where radiation injury fits among HBOT’s cancer-related uses, see our HBOT and cancer treatment guide.
Who Is Not a Good Candidate?
HBOT for radiation injury requires confirmation of no active malignancy in the treatment area, so a clear oncology assessment is standard before starting. Other general contraindications apply, including untreated pneumothorax, certain medications, and untreated ear or sinus conditions. Smoking significantly impairs the angiogenic response, and most hyperbaric programs require cessation before treatment. For cancer survivors needing reconstructive surgery in irradiated tissue, HBOT has a dual role: irradiated tissue treated before surgery develops improved vascularity, reducing wound breakdown and flap failure, which is why the RR 8.7 flap-survival finding is among the most compelling numbers in the evidence base.
Frequently Asked Questions
How long after radiation therapy can HBOT still help?
HBOT can help even when radiation injury develops years or decades after treatment. The angiogenic mechanism has no time limit, and studies include patients with osteoradionecrosis or proctitis that developed 10 or more years after radiation (Lin et al., 2023). Because radiation injury is progressive, earlier treatment once symptoms appear is generally preferable, but late presentation does not rule out benefit for the injury types HBOT addresses.
Can HBOT prevent radiation injury before it fully develops?
Prophylactic HBOT is best established for dental procedures in previously irradiated jaw tissue, where it reduces the risk of osteoradionecrosis (Lin et al., 2023). For other applications, prophylactic use is less standard, though some centers use pre-surgical HBOT to improve the vascularity of irradiated tissue before reconstruction. It is not used to prevent radiation injury generally, only in specific high-risk surgical or dental settings.
What if my radiation injury does not respond to HBOT?
Non-response or partial response does occur. Factors that reduce efficacy include very advanced tissue death, concurrent active infection, smoking, and active cancer. HBOT also shows no benefit for brain or spinal cord radiation injury (Lin et al., 2023). If HBOT fails to produce adequate response, surgical reconstruction or other interventions may be needed, coordinated with your oncology and surgical team.
Does smoking affect HBOT outcomes for radiation injury?
Yes, significantly. Smoking causes vasoconstriction and impairs angiogenesis, directly counteracting HBOT’s primary mechanism of building new blood vessels in damaged tissue. Most hyperbaric programs strongly recommend or require smoking cessation before starting a course of HBOT for radiation damage, because continuing to smoke can undermine the treatment’s main pathway to lasting improvement.
Sources
- Lin Z, Bennett MH, Hawkins G, et al. “Hyperbaric oxygen therapy for late radiation tissue injury.” Cochrane Database Syst Rev, 2023;8:CD005005. 10.1002/14651858.CD005005.pub5
- Feldmeier JJ, Hampson NB. “A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries.” Undersea Hyperb Med, 2002;29(1):4-30. PMID 12507182
- Niezgoda JA, Serena T, Carter MJ. “Outcomes of Radiation Injuries Using Hyperbaric Oxygen Therapy.” Adv Skin Wound Care, 2016;29(1):12-19. 10.1097/01.ASW.0000473679.29537.c0
- El Hadji S, Teguh D, Ridderikhof M. “Hyperbaric oxygen therapy for late radiation tissue toxicity injury after head and neck cancer.” Radiat Oncol, 2025;20:54. 10.1186/s13014-025-02680-1
- Eckert KA, Fife CE, Carter MJ. “Systematic Review of Hyperbaric Oxygen for Late Radiation Tissue Injury (Bowel, Bladder).” Undersea Hyperb Med, 2025. 10.22462/754
- Craighead P, et al. “Hyperbaric oxygen therapy for late radiation tissue injury in gynecologic malignancies.” Curr Oncol, 2011;18(5):e264-72. 10.3747/co.v18i5.767
- Spruijt NE, van den Berg R. “The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer.” Diving Hyperb Med, 2020;50(3):206-213. 10.28920/dhm50.3.206-213
- Andren J, Bennett MH. “An observational trial to establish the effect of hyperbaric oxygen treatment on pelvic late radiation tissue injury.” Diving Hyperb Med, 2020;50(3):250-255. 10.28920/dhm50.3.250-255
- Borab ZM, et al. “Systematic review of hyperbaric oxygen therapy for the treatment of radiation-induced skin necrosis.” J Plast Reconstr Aesthet Surg, 2017;70(4):529-538. 10.1016/j.bjps.2016.11.024
- Tahir AM, et al. “Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia’s largest study.” Asia Pac J Clin Oncol, 2015;11(1):68-77. 10.1111/ajco.12289
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
